A REVIEW OF VANCOMYCIN THERAPEUTIC DRUG MONITORING METHODS IN CLINICAL PRACTICE
Main Article Content
Abstract
Vancomycin is an antibiotic indicated in the treatment of severe infections with suspected or confirmed gram-positive cocci, especially methicillin-resistant Staphylococcus aureus. Due to the large variability in pharmacokinetic parameters (e.g.volume of distribution, renal clearance) among individuals, the probability of AUC/MIC target attentment of 400-600 is also very different for each patient using the same vancomycin dosage regimen. Therefore, individualizing vancomycin dose based on therapeutic dose monitoring (TDM) has been a new trend in clinical practice to optimize its effectiveness and safety. There are multiple therapeutic dose monitoring approaches for vancomycin, including TDM based on trough concentration and TDM based on AUC/MIC estimated from trough concentration, from 2 concentrations, or by Bayesian software simulation. Each method has its own advantages and disadvantages in clinical practice. Therefore, the choice of vancomycin TDM method should be considered the clinical context and implementation resources of the treatment units.
Article Details
Keywords
Vancomycin, therapeutic dose monitoring, Bayesian
References
2. Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., Rodvold, K. A., Maples, H. D., & Lomaestro, B. M. (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of HealthSystem Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 77(11), 835–864. https://doi.org/10.1093/ajhp/zxaa036.
3. Wong, J. W., Ip, M., Tang, A., Wei, V. W., Wong, S. Y., Riley, S., Read, J. M., & Kwok, K. O. (2018). Prevalence and risk factors of community-associated methicillin-resistant Staphylococcus aureus carriage in Asia-Pacific region from 2000 to 2016: a systematic review and metaanalysis. Clinical epidemiology, 10, 1489–1501. https://doi.org/10.2147/CLEP.S160595.
4. Nguyễn Tiến Dũng, Dược động dược lực học và sử dụng kháng sinh hợp lý ở trẻ em, Nhà xuất bản Y học, Hà Nội. 2022.204-214.
5. Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., Griffin, M. R., Metersky, M. L., Musher, D. M., Restrepo, M. I., & Whitney, C. G. (2019). Diagnosis and Treatment of Adults with Communityacquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American journal of respiratory and critical care medicine, 200(7), e45–e67. https://doi.org/10.1164/rccm.201908-1581ST.
6. Ye, Z. K., Tang, H. L., & Zhai, S. D. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PloS one. 2013 8(10), e77169. https://doi.org/10.1371/journal.pone.0077169.
7. Pai, M. P., Neely, M., Rodvold, K. A., & Lodise, T. P. (2014). Innovative approaches to optimizing the delivery of vancomycin in individual patients. Advanced drug delivery reviews, 77, 50–57. https://doi.org/10.1016/j.addr.2014.05.016.
8. Nguyễn Thị Cúc. Hiệu chỉnh liều vancomycin thông qua giám sát nồng độ thuốc trong máu với tiếp cận Bayesian trên bệnh nhân người lớn tại Bệnh viện Bạch Mai. Trường Đại học Dược Hà Nội, Hà Nội.2022.
9. Pongchaidecha, M., Changpradub, D., Bannalung, K., Seejuntra, K., Thongmee, S., Unnual, A., & Santimaleeworagun, W. (2020). Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting. Infection & chemotherapy, 52(4), 573–582. https://doi.org/10.3947/ic.2020.52.4.573.
10. Wicha, S. G., Märtson, A. G., Nielsen, E. I., Koch, B. C. P., Friberg, L. E., Alffenaar, J. W., Minichmayr, I. K., & International Society of Anti-Infective Pharmacology (ISAP), the PK/PD study group of the European Society of Clinical Microbiology, Infectious Diseases (EPASG) (2021). From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics. Clinical pharmacology and therapeutics, 109(4), 928–941. https://doi.org/10.1002/cpt.2202.
11. Olney KB, Wallace KL, Mynatt RP, et al. Comparison of Bayesian-derived and first-order analytic equations for calculation of vancomycin area under the curve. Pharmacotherapy. 2022;42(4):284-291. doi:10.1002/phar.2670.
12. Chen, A., Gupta, A., Do, D. H., & Nazer, L. H. Bayesian method application: Integrating mathematical modeling into clinical pharmacy through vancomycin therapeutic monitoring. Pharmacology research & perspectives, 2022. 10(6), e01026. https://doi.org/10.1002/prp2.1026.
13. Belz SN, Seabury RW, Steele JM, Darko W, Miller CD, Probst LA, Kufel WD. Accuracy of 4 Free Online Dosing Calculators in Predicting the Vancomycin Area Under the ConcentrationTime Curve Calculated Using a 2-Point Pharmacokinetic Approach. Ann Pharmacother. 2023 Apr;57(4):432-440. doi: 10.1177/10600280221117256.
14. Nguyễn Trần Nam Tiến, Lê Thị Thùy Linh, Nguyễn Hoàng Anh (b), Nguyễn Thị Cúc, Bùi Thị
Ngọc Thực và cộng sự. Thẩm định phương pháp ước đoán Bayesian ứng dung trong chỉnh liều chính xác theo mô hình (MIPD) của vancomycin trên bệnh nhân người lớn tại Bệnh viện Bạch Mai, Tạp chí Nghiên cứu Dược & Thông tin thuốc, 2022, Tập 13, số 4, trang 1-7.